<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00883623</url>
  </required_header>
  <id_info>
    <org_study_id>2008-001405-41</org_study_id>
    <secondary_id>GMIHO 005/2007 (191063)</secondary_id>
    <nct_id>NCT00883623</nct_id>
  </id_info>
  <brief_title>A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis</brief_title>
  <acronym>LEOMEX</acronym>
  <official_title>A Prospective Single Center Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With AL Amyloidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The treatment with oral melphalan and prednisone has been recommended as standard treatment&#xD;
      of AL amyloidosis but the results are rather disappointing. Another therapeutic option is&#xD;
      pulsed high-dose dexamethasone + melphalan (Mel-Dex) with more encouraging results regarding&#xD;
      the achievement of a faster disease response and higher rates of haematological remission. In&#xD;
      the last 5 - 10 years, promising treatment outcomes after therapy with high-dose melphalan&#xD;
      and autologous stem cell support have been reported by several groups but only highly&#xD;
      selected patients are eligible for this treatment. Lenalidomide has been shown to be&#xD;
      effective in phase II and III trials in MM patients. Because of the relationship to MM,&#xD;
      Lenalidomide is a promising therapeutic option also for patients with AL amyloidosis. The&#xD;
      addition of Lenalidomide to Mel-Dex could improve rate of complete response (CR) and organ&#xD;
      response in patients not eligible for or refused high-dose chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response (CR) rate</measure>
    <time_frame>6 months: after 6 cycles of L-Mel-Dex</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of hematological response (CR and PR)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ response rate</measure>
    <time_frame>3 months after discontinuation of L-Mel_Dex (maximum: 9 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of cytogenetic aberrations and gene expression profiling (GEP) results with best hematological response to treatment</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retrospective comparison with a historical control group treated with Mel-Dex in our institution</measure>
    <time_frame>01.04.2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity (hematological and non-hematological)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Primary Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Up to 6 cycles of oral L-Mel-Dex, every 28 days Revlimid® 10 mg daily for 21 days, (add on therapy), Melphalan 0.15 mg/kg/day day 1-4, Dexamethasone 20 mg day 1-4</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy proven systemic untreated AL amyloidosis requiring systemic chemotherapy&#xD;
&#xD;
          -  Not eligible for or refused HDM&#xD;
&#xD;
          -  Measurable plasma cell disease&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  WHO performance status &lt; 3&#xD;
&#xD;
          -  NYHA &lt; stage IV&#xD;
&#xD;
          -  Understand and voluntarily sign an informed consent form&#xD;
&#xD;
          -  Laboratory test results within these ranges Absolute neutrophil count &gt; 1.5 x 109/L&#xD;
             Platelet count &gt; 100 x 109/L Creatinine Clearance / MDRD &gt; 40 ml/min Total bilirubin &gt;&#xD;
             2,5 mg/dL&#xD;
&#xD;
          -  Females of childbearing potential (FCBP) must agree to use two reliable forms of&#xD;
             contraception simultaneously or to practice complete abstinence from heterosexual&#xD;
             intercourse during the following time periods related to this study: 1) for at least&#xD;
             28 days before starting study drug; 2) while participating in the study; and 3) for at&#xD;
             least 28 days after discontinuation from the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multiple Myeloma stage II and III (Durie and Salmon)&#xD;
&#xD;
          -  Previous organ transplantation&#xD;
&#xD;
          -  Not able to visit the Amyloid Clinic in Heidelberg once per month&#xD;
&#xD;
          -  Refusal of aspiration of 100 ml bone marrow at study inclusion&#xD;
&#xD;
          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that&#xD;
             would prevent the subject from signing the informed consent form.&#xD;
&#xD;
          -  Pregnant or breast feeding females. (Lactating females must agree not to breast feed&#xD;
             while taking lenalidomide).&#xD;
&#xD;
          -  Any condition, including the presence of laboratory abnormalities, which places the&#xD;
             subject at unacceptable risk if he/she were to participate in the study or confounds&#xD;
             the ability to interpret data from the study.&#xD;
&#xD;
          -  Use of any other experimental drug or therapy within 28 days of baseline.&#xD;
&#xD;
          -  Known hypersensitivity to thalidomide.&#xD;
&#xD;
          -  The development of erythema nodosum if characterized by a desquamating rash while&#xD;
             taking thalidomide or similar drugs.&#xD;
&#xD;
          -  Any prior use of lenalidomide.&#xD;
&#xD;
          -  Concurrent use of other anti-cancer agents or treatments.&#xD;
&#xD;
          -  Known positive for HIV or infectious hepatitis, B or C.&#xD;
&#xD;
          -  Patients who are in a depending position of the Sponsor or the Principal Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Schoenland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Clinic Heidelberg - Department of Internal Medicine V</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Clinic Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>April 15, 2009</study_first_submitted>
  <study_first_submitted_qc>April 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2009</study_first_posted>
  <last_update_submitted>November 21, 2013</last_update_submitted>
  <last_update_submitted_qc>November 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Dr. Stefan Schönland</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>AL-Amyloidosis</keyword>
  <keyword>Lenalidomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulin Light-chain Amyloidosis</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

